Xbrane Biopharma AB (publ)

kr 12.70As of Sun 8 Nov 2026, 12:00 UTC
STO:XBRANEHealthcare
Country Sweden
PE (Fwd) •••
TSR 10Y CAGR (44.57%)
Div yield —
ROE (11.10%)
Biotechnology
Beta (5Y) 0.70
PE TTM —
TSR TTM 18.69%
Mkt cap kr 261.7M
ROIC (6.56%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
kr 15
14.21%
285.68%
Hold 11|10|6|7|0
4Q25
1Q26
2Q26
3Q26
Earnings per sharekr
0.20
0.22
0.24
0.26
7.36%
5.24%
11.36%
22.79%
Revenuekr M
24.09
23.40
24.15
23.83
4.92%
1.89%
6.05%
1.93%
Peers (US$26.46M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
1.085
(0.040)
(0.039)
EBIT/Intx
1.025
1.534
1.658
Own earn%
(336.92)
93.34
64.99
Sh yield%
25.61
60.43
60.41
Owners
Insiders/Inst%
12.95
83.04
Short interest%
1.75
SBC / revenue%
4.45
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
1–5
$1 testx
—
Incr. ROIC%
3